Pembrolizumab received FDA approval in June 2020 for locally advanced or metastatic cSCC but remains unapproved by EMA, leaving cemiplimab as the sole approved PD-1 inhibitor for advanced cSCC in Europe. Here, PDCD1 is linked to skin squamous cell carcinoma.